重复TAVR与TAVR瓣膜取出术的长期结局:全国性分析
该全国性分析比较了Medicare受益者在初次TAVR后因生物瓣功能障碍接受再次干预的长期结局。在倾向性匹配队列中,TAVR瓣膜取出术的30天和90天死亡率更高,但3年和5年累积死亡率更低,生存曲线约在9个月交叉。全随访期风险比为0.61(95%CI 0.49-0.75;P<.001),长期结局倾向于TAVR瓣膜取出术。
要点
- TAVR瓣膜取出术短期死亡率较高,但长期生存优于重复TAVR。
- 生存曲线约在9个月交叉,此后TAVR瓣膜取出术持续获益。
- 全随访期风险比0.61(95%CI 0.49-0.75;P<.001)支持瓣膜取出术。
核心结论
- 尽管重复TAVR短期死亡率更低,但长期结局更支持TAVR瓣膜取出术。
- 对于TAVR失败的Medicare受益者,部分患者可能从TAVR瓣膜取出术中获益。
研究设计与样本
- 基于Medicare受益者的全国性回顾性队列分析,纳入2012年1月至2020年12月初次TAVR后接受主动脉瓣再干预的患者。
- 共1172例接受再干预,其中70.6%为重复TAVR,29.4%为TAVR瓣膜取出术;采用Kaplan-Meier曲线和1:1倾向性匹配分析调整后结局。
主要发现
- 重复TAVR患者年龄更大、女性更多、Charlson合并症评分更高(均P<.05)。
- 中位随访29.2个月(重复TAVR 27.7个月,TAVR瓣膜取出术32.3个月)。
- 倾向性匹配队列中,TAVR瓣膜取出术30天和90天死亡率更高,但3年和5年累积死亡率更低(均P<.001)。
- 生存曲线约在9个月交叉,此后TAVR瓣膜取出术持续优势;全随访期风险比0.61(95%CI 0.49-0.75;P<.001)。
- Charlson合并症分层及排除同期手术后,生存模式相似。
临床怎么用
- TAVR失败后选择再干预方式时,需权衡重复TAVR的短期低死亡风险与瓣膜取出术的长期生存获益。
- 对于预期寿命较长、可耐受手术的TAVR失败患者,TAVR瓣膜取出术可能带来长期生存优势。
局限性
- 原文未报告具体局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Comparative durability of subsequent procedures after transcatheter aortic valve replacement (TAVR) remains unclear. This study aimed to assess long-term outcomes of repeated TAVR vs TAVR explantation for bioprosthetic valve dysfunction after TAVR. METHODS: Medicare beneficiaries undergoing aortic valve reintervention after index TAVR (January 2012-December 2020) were assigned to repeated TAVR or TAVR explantation categories. Exclusion criteria included endocarditis or reintervention during the same admission. Primary outcome was 5-year mortality; secondary outcomes included major adverse cardiovascular events (death, pacemaker placement, major bleeding, stroke, acute kidney injury, cardiac arrest). Time-to-event analyses used Kaplan-Meier curves. Adjusted outcomes were assessed by 1:1 propensity matching. RESULTS: Of 1172 patients undergoing reintervention after TAVR, 70.6% had repeated TAVR and 29.4% had TAVR explantation. Repeated TAVR patients were older and more often female, with higher Charlson comorbidity score (all P < .05). Median follow-up was 29.2 months (27.7 months repeated TAVR, 32.3 months TAVR explantation). In the propensity score-matched cohorts, 30- and 90-day mortality was higher after TAVR explantation, but Kaplan-Meier estimated cumulative mortality was lower in TAVR explantation at 3 and 5 years (all P < .001). Survival curves crossed at approximately 9 months, after which TAVR explantation maintained a persistent advantage. The hazard ratio during the entire follow-up was 0.61 (95% CI, 0.49-0.75; P < .001). Similar survival patterns were observed across Charlson comorbidity stratification and after exclusion of concomitant procedures. CONCLUSIONS: Although repeated TAVR showed lower short-term mortality, long-term outcomes favored TAVR explantation. These findings suggest that for Medicare beneficiaries experiencing TAVR failure, there is a subset of patients who could benefit from TAVR explantation over repeated TAVR.
引用
- Faggion Vinholo T, Awtry J, Cho M, et al. Long-Term Outcomes of Repeated Transcatheter Aortic Valve Replacement vs Transcatheter Aortic Valve Replacement Explantation: A Nationwide Analysis. Ann Thorac Surg. 2026. PMID: 41564916. doi:10.1016/j.athoracsur.2025.12.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。